A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer.

Br J Cancer · 2013 · PMC3566804 · PMID 23329236

Europe PMC DOI

hedged sentences

0.0507

closest p · 1.0× alpha

0.1180

boldest claim

The sentences

a strong trendP =0.0507so close (0.05 < p ≤ 0.1)

Grade 3/4 infections had a strong trend to occur more frequently with Cis/Doc (26% vs 9%, P =0.0507).

also in 5,725 other papers

did not reach statistical significanceP =0.118not close (p > 0.1)

The response rate, which was the primary end point, was in favour of Cis/Doc, with 47% (95% CI: 32.5–61.0%) vs 28% (95% CI: 16.6–42.8%) with Ox/Doc, but this did not reach statistical significance ( P =0.118; Table 3 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.